• I-BET151 in Cancer Biology: Evidence and Limits

  2026-10-05

  A source-grounded overview of I-BET151 (GSK1210151A), its reported BET bromodomain activity, conceptual relevance to cancer biology, and the limitations of connecting supplier-described effects with emerging prostate cancer research on the super-enhancer–FOXA1–SLC7A11 axis.

• Sulfo-Cy3 NHS Ester in Vascular Translation

  2026-10-05

  A mechanistic perspective on how hydrophilic fluorescent labeling can help translational researchers interrogate the AIBP–LRP2–HDL–miR-223 axis and CXCR4-positive endothelial plasticity in ischemic vascular disease.

• Brain-to-Spinal Control of Opioid Hypersensitivity

  2026-10-04

  A 2024 Neuron study identifies a brain-to-spinal opioid pathway that regulates morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. The findings expand opioid receptor pharmacology beyond peripheral and thermal mechanisms by implicating coordinated MOR, dynorphin, KOR, and spinal GABAergic circuits.

• ARCA Cy5 EGFP mRNA: Evidence and Research Context

  2026-10-03

  A source-grounded overview of ARCA Cy5 EGFP mRNA (5-moUTP), emphasizing its conceptual value for studying mRNA localization and translation, the relevance of peptide-based pulmonary delivery research, and the limits of supplier descriptions and in vitro evidence.

• Difloxacin HCl: Applied Research Workflows

  2026-10-02

  Difloxacin HCl supports two distinct research workflows: bacterial antimicrobial susceptibility testing and transporter-linked multidrug resistance reversal. This guide translates its DNA gyrase activity, formulation properties, and the p31comet checkpoint study into practical assay design, controls, and troubleshooting strategies.

• AIBP–LRP2–HDL Control of Collateral Growth

  2026-10-01

  The reference study identifies an AIBP–LRP2–HDL–miR-223 pathway that suppresses CXCR4-positive, stemlike capillary endothelial cells during ischemic vascular remodeling. By combining human PAD profiling with murine ischemia experiments and genetic and mechanistic analyses, it proposes a two-phase model in which transient expansion of CXCR4-positive capillary cells precedes their remodeling into functional collaterals.

• Atorvastatin: A Translational Bridge to Ferroptosis

  2026-10-01

  Atorvastatin is best understood not only as an HMG-CoA reductase inhibitor, but also as a translational probe linking mevalonate biology, vascular remodeling, endoplasmic reticulum stress, and ferroptosis. This article interprets recent hepatocellular carcinoma evidence and converts it into practical guidance for researchers designing reproducible, cross-domain studies.

• Thrombin B Chain Fragment in Fibrin Assay Workflows

  2026-09-30

  A1057 provides a defined human thrombin B-chain peptide for identity controls, matrix studies, and mechanistic experiments that must distinguish sequence effects from full-length enzyme activity. This guide translates fibrin-matrix angiogenesis findings into practical workflows while highlighting where the fragment should not be treated as catalytically active thrombin.

• EZ Cap Cy5 Firefly Luciferase mRNA: Assay Logic

  2026-09-30

  EZ Cap Cy5 Firefly Luciferase mRNA enables researchers to separate cellular delivery, intracellular trafficking, and protein expression in one dual-reporter workflow. This article connects its Cap1 and 5-moUTP design to practical assay decisions inspired by recent lipid nanoparticle genome-editing research.

• CFTRinh-172: A Practical CFTR Inhibitor Workflow

  2026-09-29

  CFTRinh-172 provides a fast, reversible way to separate CFTR-dependent chloride transport from upstream cAMP signaling in airway and intestinal epithelial models. This guide translates its selectivity, rapid onset, and preclinical fluid-secretion data into practical workflows for cystic fibrosis research, trafficking studies, and secretory disease assays.

• ω-Agatoxin IVA TFA: From Blockade to Biology

  2026-09-29

  ω-Agatoxin IVA TFA is a selective Cav2.1 channel probe for connecting calcium entry with synaptic release, seizure activity, and neuronal survival. This guide translates its pharmacology and rat-model evidence into practical assay decisions.

• Atorvastatin: From Mevalonate to Ferroptosis

  2026-09-28

  Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a versatile probe for connecting cholesterol metabolism, redox biology, ferroptosis, and vascular phenotypes. This article translates recent HCC findings into practical assay and interpretation strategies.

• Atorvastatin Beyond Lipids: Vascular Biology to HCC

  2026-09-28

  Atorvastatin is best known as an HMG-CoA reductase inhibitor, but its research value reaches beyond cholesterol lowering. This article examines the mechanistic bridge between mevalonate-pathway biology, vascular research, and a 2025 study identifying atorvastatin as a potential ferroptosis-inducing agent in hepatocellular carcinoma—while clarifying what the evidence does and does not establish.

• ARCA EGFP mRNA (5-moUTP) for Cell Assays

  2026-09-27

  Build a more interpretable mammalian-cell transfection assay with a fluorescent reporter that helps separate delivery performance from downstream protein expression. This guide pairs a practical dose-and-time workflow with careful handling advice—and explains why an LNP storage study informs assay rigor, not the storage conditions for this product.

• DAMGO as a Probe of Opioid Pain Circuitry

  2026-09-26

  DAMGO is a selective µ-opioid receptor agonist that can help separate receptor activation from the effects of repeated opioid exposure. This article connects its pharmacology to a 2024 mouse study of mechanical hypersensitivity and shows how to design experiments that distinguish receptor-level activity from circuit-level outcomes.

7822 records 1/522 page Next 12345 下5页 Last page